Premium
Peripheral CB1R as a modulator of metabolic inflammation
Author(s) -
Han Ji Hye,
Kim Wook
Publication year - 2021
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.202001960r
Subject(s) - insulin resistance , dyslipidemia , inflammation , metabolic syndrome , adipose tissue , endocannabinoid system , medicine , cannabinoid receptor , hormone , mediator , insulin , endocrinology , bioinformatics , diabetes mellitus , biology , receptor , antagonist
Obesity is associated with chronic inflammation in insulin‐sensitive tissues, including liver and adipose tissue, and causes hormonal/metabolic complications, such as insulin resistance. There is growing evidence that peripheral cannabinoid‐type 1 receptor (CB1R) is a crucial participant in obesity‐induced pro‐inflammatory responses in insulin‐target tissues, and its selective targeting could be a novel therapeutic strategy to break the link between insulin resistance and metabolic inflammation. In this review, we introduce the role of peripheral CB1R in metabolic inflammation and as a mediator of hormonal/metabolic complications that underlie metabolic syndrome, including fatty liver, insulin resistance, and dyslipidemia. We also discuss the therapeutic potential of second‐ and third‐generation peripherally restricted CB1R antagonists for treating obesity‐induced metabolic inflammation without eliciting central CB1R‐mediated neurobehavioral effects, predictive of neuropsychiatric side effects, in humans.